XBRU:TUB (Belgium)
Business Description
Financiere de Tubize SA
NAICS : 325412
Allée de la Recherche, 60, Brussels, BEL, 1070
Compare
Compare
Traded in other countries / regions
TUB.Belgium
•
FTD.Germany
•
0D53.UK
Description
Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.01 | |||||
| Equity-to-Asset | 0.99 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.14 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 9.8 | |||||
| 3-Year EPS without NRI Growth Rate | 10.1 | |||||
| 3-Year FCF Growth Rate | -2.7 | |||||
| 3-Year Book Growth Rate | 6.7 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 23.41 | |||||
| 9-Day RSI | 28.31 | |||||
| 14-Day RSI | 31.97 | |||||
| 6-1 Month Momentum % | -10.87 | |||||
| 12-1 Month Momentum % | -14.99 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.01 | |||||
| Quick Ratio | 0.01 | |||||
| Cash Ratio | 0.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.05 | |||||
| Dividend Payout Ratio | 0.1 | |||||
| 3-Year Dividend Growth Rate | 8 | |||||
| Forward Dividend Yield % | 1.05 | |||||
| 5-Year Yield-on-Cost % | 1.42 | |||||
| 3-Year Average Share Buyback Ratio | -4.5 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | 9.87 | |||||
| ROA % | 9.8 | |||||
| ROIC % | -0.05 | |||||
| ROCE % | 9.87 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.94 | |||||
| PE Ratio without NRI | 9.94 | |||||
| Shiller PE Ratio | 14.27 | |||||
| PEG Ratio | 0.96 | |||||
| PB Ratio | 0.91 | |||||
| Price-to-Tangible-Book | 0.91 | |||||
| EV-to-EBIT | 8.48 | |||||
| EV-to-EBITDA | 8.48 | |||||
| EV-to-FCF | -2897.4 | |||||
| Price-to-Projected-FCF | 1.23 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.8 | |||||
| Price-to-Graham-Number | 0.64 | |||||
| Earnings Yield (Greenblatt) % | 11.79 | |||||
| Forward Rate of Return (Yacktman) % | 10.38 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0 | ||
| EPS (TTM) (€) | 7.19 | ||
| Beta | 0.56 | ||
| Volatility % | 25.08 | ||
| 14-Day RSI | 31.97 | ||
| 14-Day ATR (€) | 1.809973 | ||
| 20-Day SMA (€) | 75.155 | ||
| 12-1 Month Momentum % | -14.99 | ||
| 52-Week Range (€) | 70.9 - 100.8 | ||
| Shares Outstanding (Mil) | 44.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Financiere de Tubize SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||